banner
 
bar

program

slides
bar
 
 

Pivotal Treatment Advances in Biologic Therapy for Atopic Dermatitis (AD)

WebCAST

 

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

1.0 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in atopic dermatitis

Release Date

November 11, 2016

Expiration Date

November 11, 2018

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period November 11, 2016 through November 11, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 5 segments totaling 1.0 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

Accreditation Statement

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Massachusetts School of Medicine, Office of CME, and CMEducation Resources, LLC. University of Massachusetts School of Medicine, Office of CME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

University of Massachusetts School of Medicine, Office of CME requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

PROFESSOR MARK LEBWOHL, MD
PROGRAM CO-CHAIR

Professor and Chairman
Department of Dermatology
The Mount Sinai School of Medicine
New York, New York, USA

Advisor or consultant: AbbVie Inc.; AbGenomics International Inc.; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Aqua Pharmaceuticals; Can-Fite Biopharma, Ltd.; Celgene Corporation; Clinuvel Pharmaceuticals Ltd; Coronado Biosciences; Ferndale Laboratories, Inc.; Janssen Biotech, Inc.; LEO Pharmaceuticals, Inc.; Eli Lilly and Company; Merz Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sandoz; Valeant Pharmaceuticals International
Grant/Research Support: AbbVie Inc.; AbGenomics International Inc.; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Aqua Pharmaceuticals; Can-Fite Biopharma, Ltd.; Celgene Corporation; Clinuvel Pharmaceuticals Ltd; Coronado Biosciences; Ferndale Laboratories, Inc.; Janssen Biotech, Inc.; Kadmon Corporation, LLC; LEO Pharma, Inc.; Eli Lilly and Company; Merz Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sandoz; Valeant Pharmaceuticals International



PROFESSOR EMMA GUTTMAN, MD, PhD
Professor and Vice Chair, Dermatology
Director, Center for Excellence in
Eczema and Laboratory for
Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Medical Center
New York, New York, USA

Advisor or Consultant: AbbVie Inc.; Anacor Pharmaceuticals, Inc.; Celgene Corporation; Celsus Therapeutics Plc; Dermira Inc.; Galderma Laboratories, L.P.; Glenmark; LEO Pharma Inc.; Lilly; MedImmune Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Stiefel Laboratories, Inc.; Vitae Pharmaceuticals, Inc.
Grant/Research Support: Celgene Corporation; Dermira Inc.; Janssen Biotech, Inc.; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.
Investigator: Celgene Corporation; MedImmune Inc.; Regeneron Pharmaceuticals, Inc.
Honorarium: AbbVie Inc.; Anacor Pharmaceuticals, Inc.; Celgene Corporation; Celsus Therapeutics Plc; Dermira Inc.; Galderma Laboratories, L.P.; Glenmark; LEO Pharma Inc.; Lilly; MedImmune Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Stiefel Laboratories, Inc.; Vitae Pharmaceuticals, Inc.



PROFESSOR ERIC SIMPSON, MD
PROGRAM CO-CHAIR

Professor and Director of Clinical Trials Department of Dermatology
Oregon Health and Science University Portland, Oregon, USA

Consultant: Regeneron, Genentech, Celgene, Anacor, MedImmune
Grant/Research Support: Galderma, Regeneron, Genentech, Anacor, MedImmune



PROFESSOR MICHAEL J. CORK, MD
Head of Academic Dermatology Research Department of Infection and Immunity
The University of Sheffield Medical School Sheffield, United Kingdom

Grant/Research Support: Wellcome Trust, Leo, Kuwait Ministry of Health, NIHR, Anacor, Almirall, Johnson & Johnson, Sanofi – Genzyme, Regeneron, Astellas, Stiefel-GSK, Bayer Dermatology, Pfizer

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose. Program reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Manage patients with moderate-to-severe atopic dermatitis;
  • Apply national and international professional association-based guidelines for assessment and diagnosis of atopic dermatitis to the front line of patient care;
  • Apply national and international professional association-based guidelines for management of atopic dermatitis to the front line of patient care;
  • Detail the epidemiology, disease burden, and quality-of-life dimensions associated with atopic dermatitis based on severity of disease and health care disparities;
  • Sequence and combine non-pharmacologic and pharmacologic therapies based on severity of disease, biomarkers, and guideline-directed roadmaps for optimizing management of atopic dermatitis;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2016 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

Alefacept
AN2728
anti-IL-4Rα
atopic dermatitis
Azathioprine
Azathioprine
cream in Phase 2

(AstraZeneca)
Cyclosporine
Dupilumab
Efalizumab
effects on the epidermis in AD
IL-17

 

Imuran
JAK inhibitor
Methotrexate
MTX
Mycophenolate mofetil
Mycophenolate Mofetil
NBUVB

PDE4 inhibitors
Probiotics
roflumilast
Th2 Cytokine
Tofacitinib
urticaria
Vitamin D